Michèle is a co-founder and Partner at Medicxi. Prior to Medicxi, Michèle was a partner at Index Ventures for 10 years, having joined the firm in 2006. She currently serves on the boards of a number of portfolio companies, including Kaerus Biosciences, Palladio Biosciences and Gadeta. Michèle’s prior investments include OncoEthix (Sold to Merck Pharmaceuticals) and Aegerion (NASDAQ: AEGR).
Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years and also spent more than 15 years in senior roles at Sanofi, Bristol Myers Squibb, RPR Gencell and Serono International.
Michèle completed her medical studies in France at Paris Ouest University. Michèle also serves on the board of Ipsen Pharmaceuticals (Euronext:IPN) and sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord.